WO2011061144A2 - Utilisation de bêta-(1,3)-bêta-(1,4)-glucane ayant une masse moléculaire moyenne de 5 000 à 150 000 da pour augmentation de synthèse du collagène - Google Patents

Utilisation de bêta-(1,3)-bêta-(1,4)-glucane ayant une masse moléculaire moyenne de 5 000 à 150 000 da pour augmentation de synthèse du collagène Download PDF

Info

Publication number
WO2011061144A2
WO2011061144A2 PCT/EP2010/067460 EP2010067460W WO2011061144A2 WO 2011061144 A2 WO2011061144 A2 WO 2011061144A2 EP 2010067460 W EP2010067460 W EP 2010067460W WO 2011061144 A2 WO2011061144 A2 WO 2011061144A2
Authority
WO
WIPO (PCT)
Prior art keywords
beta
glucan
molecular weight
acid
collagen
Prior art date
Application number
PCT/EP2010/067460
Other languages
English (en)
Other versions
WO2011061144A3 (fr
Inventor
Marvin Karos
Heiko Barg
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of WO2011061144A2 publication Critical patent/WO2011061144A2/fr
Publication of WO2011061144A3 publication Critical patent/WO2011061144A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998—Hordeum (barley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to the use of beta-(1 , 3)- beta-(1 , 4) glucan with an average molecular weight of from 5.000 to 150.000 Da for the increase of synthesis of collagen
  • Glucans are homopolysaccharides consisting of glucose only.
  • Glucans are distinctive polymers of glucose differentiated from other polymers by not only their source but also their physicochemical properties. However, different stereo chemical conformations exist, since it is possible to link the glucose molecules in different ways.
  • glucans are a diverse group of compounds with differing chemical, physical, and functional properties. The influence of the chemical structure of polysaccharides on their properties can be appreciated by comparing the common properties of some common homo- glucans.
  • Dextran a (1 , 6)-[alpha]-glucan, with a small degree of branching, is extremely water soluble and non-gel forming.
  • Amylose an (1 , 4)-[alpha]-D-glucan, is sparingly soluble in water and can form rigid thermo-reversible gels.
  • Oat [beta]-(1 , 3)-[beta]-(1 , 4)-glucan is classified as a viscous gum, (see Wood, PJ 1 5 (1993) Oat Bran Ed PJ Wood (American Association of Cereal Chemists, Inc. St. Paul, MN)).
  • Unmodified oat [beta]-(1 , 3)-[beta]-(1 , 4)-glucan forms highly viscous solutions in water at concentrations >0.75 %wt. At concentrations >1 .2 %wt. the solu- tions have the consistency of a thick hydro gel.
  • Cereal [beta]-(1 ,3)-[beta]-(1 ,4)-glucans are structural polysaccharides present in the cell wall of cereals like barley and oat, among others.
  • Oat [beta]-(1 ,3)-[beta]-(1 ,4)- glucan, is recognized by the U.S. FDA as an agent that may aid the prevention of heart disease. In 1997, the FDA allowed oat products to make a health claim.
  • Glucans derived from yeast, fungi, certain bacteria and genetically engineered bacteria are of significantly different molecular structure and have different physical and chemical properties compared to cereal, e.g. barley or oat glucan.
  • beta-glucan refers to those polysaccharides which comprise beta- glu- copyranosyl units which are linked together by (1 , 3) and (1 , 4) beta- linkages, beta- Glucans occur naturally in many cereal grains such as oats and barley.
  • the molecular weight of beta-glucan molecules occurring in cereals is typically 200 to 2000 kilo Daltons.
  • Beta-Glucan is a water-soluble polysaccharide consisting of linear chains of glucose units with 1 -3 and 1 -4 linkages and has a mean molecular weight in the range of 500,000 - 1 ,000,000, typically of about 1 million kDa.
  • beta-glucan is desirable as a food additive, for example, to impart texture ("mouth feel") to foods, beta-glucan is also useful for preparing edible films for food coatings, beta- glucan may also be used to add bulk to foods and has the advantage of having a neutral flavour. beta-glucan is also desirable as a therapeutic agent.
  • beta-glucan can lower serum cholesterol levels, heal wounds, moderate glycaemic response, and alleviate constipation, beta-glucan can actively bind to specific cell receptors and therefore may be useful for the treatment of a wide variety of disorders or diseases.
  • WO 2005/048735 and WO2005/122785 disclose a method for the extraction of soluble fibers from oat and barley.
  • WO01/57092 describes a process for obtaining beta -glucan from cereal grain, such as barley and oats.
  • a beta -glucan product obtained by the process. Uses of the beta - glucan product as a food ingredient and for treating various diseases or disorders.
  • the process includes the steps of forming flour from the cereal grain, mixing the flour with water to form a slurry of a process for obtaining beta -glucan from cereal grain including forming flour from the cereal grain, mixing the flour with water to form a slurry of an aqueous solution of beta -glucan and a solid residue, separating the aqueous solution from the solid residue, and removing water from the aqueous solution by evaporation or ultra filtration or combinations thereof to form a beta -glucan containing gel or solid
  • WO02/02645 describes a process for preparing the beta -glucan by recovering the beta -glucan from an aqueous solution containing it before any gelation of the solution begins to occur.
  • the beta-glucan is useful for a range of therapies. These include the lowering of serum cholesterol levels, wound healing, the regulation of glycaemic response, the stimulation of the immune system, and the alleviation of constipation. It is thought that beta-glucan can actively bind to specific cell receptors and is therefore useful for treating a variety of diseases or disorders.
  • WO98/13056 describes a process for obtaining beta -glucan from cereal by extracting with water and without deactivation of enzymes associated with the cereal, a process for controlling the average molecular weight of beta -glucan extracted from cereal by controlling the extraction time, a process for recovering beta -glucan from an aqueous solution of beta -glucan comprising freezing the solution, allowing the solution to thaw and separating solids from the resultant suspension, a beta -glucan produced by any of these processes with an average molecular weight in the range up to 1 ,500,000, which forms a gel when a heated solution of the beta -glucan cools and the use of beta - glucan in treating various health disorders, as an additive in cosmetics such as moisture cream and foods, and as a film forming agent.
  • WO2006/015627 describes the use of beta-(1 ,3)-beta-(1 ,4)-glucan (a) as carrier for carrying a chemical substance through the stratum corneum into deeper layers of the skin and/or (b) for improving the penetration abilities of the chemical substance through the stratum corneum into deeper layers of the skin.
  • Oat Glucan is able to form a complex with actives such as cosmetical, therapeutical and/or pharmaceutical actives without being covalently bound to these actives.
  • the WO2006/015627 further relates to a topical composition
  • a topical composition comprising a mixture of (a) [beta]- (1 ,3)-[beta]-(1 ,4)-glucan and (b) at least one cosmetical, therapeutical and/or pharmaceutical active.
  • the [beta]-(1 ,3)-[beta]-(1 ,4)-glucan according to WO2006/015627 preferably has a mean molecular weight of 10,000 to 5,000,000 g/mol, more preferably a mean molecular weight of 100,000 to 1 ,500,000 g/mol.
  • EP 0 476 063 describes pharmaceutical compositions comprising a drug chemically bound to or being contained within whole beta-glucan particles.
  • a whole beta-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use, is taught.
  • a drug is incorporated into a whole beta-glucan micro particle, and the combination is administered to an individual.
  • the beta-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.
  • WO 96/14873 discloses a glucan composition containing a beta-1 ,3-glucan covalently attached to a bioactive agent.
  • the beta-1 ,3-glucan is attached to the bioactive agent by means of a hydrolysable covalent linkage to form a glucan/agent product. Also disclosed are methods relating to said product, including a method for the treatment of a pathogen capable of invading or colonizing phagocytic cells, and a method for deliver- ing an antigen to a phagocytic cell.
  • US 5,676,967 discloses a wound dressing for covering a wound of the body, providing slow release of a combination of collagenic protein and oligosaccharide, enhancing vapor transmission from the wound, and enhancing healing. It comprises an aqueous combination of collagen and oligosaccharide coated on a mesh surface and dehydrated to a low moisture content.
  • the mesh netting used has holes or openings, and the structure of the netting permits a solution of oligosaccharide such as glucan and a collagen to impregnate and fill the openings. The impregnated netting is then dehydrated and oligosaccharide and collagen are deposited and adhere to the fibers.
  • An aqueous based mixture of the oligosaccharide and collagen for impregnating the mesh netting may contain about 1 -10 percent oligosaccharide and 1 -15 percent collagen. The mixture is applied to the mesh netting to substantially impregnate it.
  • An aqueous- based solution of oat-derived beta-D-glucan and bovine collagen containing Type I and Type III collagens was prepared and the mesh netting impregnated therewith.
  • EP 1 046 394 is directed to compositions and their use for delivering compounds into a cell.
  • the compositions comprise, in combination with the compound to be delivered, an organic halide, a targeting ligand, and a nuclear localization sequence, optionally in the presence of a earner.
  • the composition comprises a carrier or stabilizing materials, a large number of polymers may be used, inter alia glucans are suitable.
  • the compositions are particularly suitable for the treatment of inflammatory diseases.
  • WO 01/87255 relates to an external application having enhanced skin absorbency of the active agents by using protease stabilized by beta-1 ,3- glucan branched with beta-1 ,6-linkage as an agent for enhancing the skin absorption. Stabilization of the protease is achieved by a chemical reaction in order to covalently bind the protease to the beta-glucan, the resulting product is then able to enhance the skin absorption of the active agents.
  • WO 03/054077 teaches the use of beta glucan as a film forming delivery system for controlled delivery of actives into an aqueous system, i.e. the mouth cavity.
  • Cereal [be- ta]-(1 ,3)-[beta]- (1 ,4)-glucan is used as a film or coating agent to produce clear, edible, biodegradable, delivery, lubricating, and protecting agents.
  • the [beta]-(1 ,3)-[beta]-(1 ,4)- glucan forms a matrix to sequester other materials, such as pharmaceutical, medical and therapeutic agents, flavours, fragrances.
  • the technology has applications to essential oils and non-aqueous materials that are rendered deliverable by the [beta]-(1 ,3)- [beta]-(1 ,4)-glucan.
  • the [beta]-(1 ,3)-[beta]-(1 ,4)- glucan films described may be con- sumed whereby they dissolve in the mouth in a controlled manner and may be used for the delivery of pharmaceutical, medical or confectionery products.
  • Beta-(1 , 3)- beta-(1 , 4) glucan with a low molecular weight can have a great influence on the synthesis of collagen.
  • beta-(1 , 3)- beta-(1 , 4) glucan with an average molecular weight of from 5.000 to 150.000 Da for the increase of cell proliferation and/or viability or as anti-inflammatory substance or for the protection of at least one endogenous growth factor.
  • the present invention relates to the non-therapeutic use of beta-(1 ,3)- beta-(1 ,4) glucan with a mean molecular weight of from 5.000 to 150.000 Da for the increase of syn- thesis of collagen.
  • the MW is from 13.000 to 60.000 Da, particularly 20.000 to 50.000 Da.
  • the soluble collagen produced in human dermal fibroblasts will be significantly increased after treatment with the low molecular weight glucan according to the present invention.
  • the mean MW is 20.000 Da.
  • the mean MW is 50.000 Da.
  • This low molecular weight is ex- pected to show a much higher synthesis of collagen compared to a beta glucan with a molecular weight of 1 ,5 million Da according to the state of the art as it is much smaller and able to penetrate easier through the skin and interact much better in the cell.
  • the low molecular weight beta glucan according to the intervention just has 1 , 3 and 1 , 4 linkages and does not contain any 1 , 6 linkage between the glucose monomers.
  • the glucan is prepared from a cereal, preferably from barley.
  • the glucan can also be prepared from other cereals, which show the same molecular structure in the glucan such as oat, or other cereals.
  • the range of the molecular weight of the beta glucan depends on the mean molecular weight off the glucan. The lower the mean molecular weight, the broader the range can be. For a mean molecular weight of from 5000 to 20,000 Da the lower end of the range is about 10% of the mean molecular weight and the upper end of the range is about 200% of the mean molecular weight. In a preferred embodiment the range is from about 2000 to about 40,000 Da for a mean molecular weight off 20,000 Da.
  • the range of molecular weight is from about 40,000 to about 60,000 Da for a mean molecular weight off 50,000 Da.
  • the beta glucan can be used at a concentration of from 0.0001 % to 10 %. In a preferred embodiment the beta glucan is used at a concentration in the range from 0.001 % to 2 %, preferably 0.1 % to 2 %, more preferably from 0.5 % to 1.5 %, particularly at 1 %. Most preferably the beta glucan with a mean molecular weight of 50,000 Da is used at a concentration of 1 %. Alternatively the beta glucan with a mean molecular weight of 20,000 Da can be used at a concentration of 1 %. The dose depends on the individual MW for each application and it is also possible to apply the glucan at 0,5 % or 0,1 %.
  • the beta glucan according to the present invention can be used with any standard ingredients of cosmetic products as well as with other active compounds in cosmetic protests.
  • the following gives some examples of possible ingredients or active com- pounds which can be used together with the beta glucan according to the invention.
  • the invention also relates to a cosmetic composition
  • a cosmetic composition comprising -(1 ,3)- beta-(1 ,4) glucan with a mean molecular weight of less than 50.000 Da.
  • the cosmetic compositions according to the invention may be skin cosmetic, nail cosmetic, hair cosmetic, derma- tological, hygiene or pharmaceutical compositions.
  • auxiliaries and additives for producing hair cosmetic, nail cosmetic or skin cosmetic preparations are known to the person skilled in the art and can be found in handbooks of cosmetics, for example Schrader, Klan und Phuren der Kos- metika [Fundamentals and formulations of cosmetics], Huthig Verlag, Heidelberg, 1989, ISBN 3-7785-1491 -1.
  • compositions according to the invention are in the form of a gel, foam, spray, ointment, cream, emulsion, suspension, lotion, milk or paste. If desired, lipo- somes or microspheres can also be used.
  • compositions according to the invention can additionally comprise cosmetically and/or dermatologically active ingredients and auxiliaries.
  • the cosmetic compositions according to the invention comprise at least one beta-glucanas defined above, and at least one constituent different therefrom which is chosen from cosmetically active ingredients, emulsifiers, surfactants, preservatives, perfume oils, thickeners, hair polymers, hair and skin conditioners, graft polymers, wa- ter-soluble or dispersible silicone-containing polymers, photoprotective agents, bleaches, gel formers, care agents, colorants, tints, tanning agents, dyes, pigments, consistency regulators, moisturizers, re-fatting agents, collagen, protein hydrolysates, lipids, antioxidants, antifoams, antistats, emollients and softeners.
  • the beta-glucan active ingredients may also be present in encapsulated form in the cosmetic preparations.
  • the antioxidants are chosen from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazoles (e.g. urocanic acid) and derivatives thereof, peptides such as D,L-carnosine, D-carnosine, L- carnosine and derivaties thereof (e.g. anserine), carotenoids, carotenes (e.g. ⁇ - carotene, lycopene) and derivatives thereof, chlorogenic acid and derivatives thereof, lipoic acid and derivatives thereof (e.g.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. urocanic acid
  • peptides such as D,L-carnosine, D-carnosine, L- carnosine and derivaties thereof (e.g. anserine)
  • carotenoids e.g
  • thioredoxin glutathione, cysteine, cystine, cystamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters thereof
  • salts thereof dilauryl thiodipropi- onate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts), and sulfoximine com- pounds (e.g.
  • buthionine sulfoximines in very low tolerated doses (e.g. pmol to ⁇ /kg), also (metal) chelating agents (e.g. a-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
  • citric acid citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA and derivatives thereof
  • unsaturated fatty acids and derivatives thereof e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and derivatives thereof ubiquinone and ubiquinol and derivatives thereof
  • vitamin C and derivatives thereof e.g. sodium ascorbate, ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate
  • tocopherol and derivatives e.g.
  • vitamin E acetate, to- cotrienol
  • vitamin A and derivatives vitamin A palmitate
  • coniferyl benzoate of benzoin resin rutinic acid and derivatives thereof, a-glycosyl rutin, ferulic acid, fur- furylideneglucitol, carnosine, butylhydroxytoluene, butylhydroxyanisole, nordihy- droguaiacic acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and derivatives thereof, mannose and derivatives thereof, zinc and derivatives thereof (e.g. ZnO, ZnS04), selenium and derivatives thereof (e.g. selenomethionine), stilbenes and derivatives thereof (e.g. stilbene oxide, trans-stilbene oxide).
  • rutinic acid and derivatives thereof e.g. a-glycosyl rutin, ferulic acid, fur- furylideneglucitol
  • Customary thickeners in such formulations are crosslinked polyacrylic acids and derivatives thereof, polysaccharides and derivatives thereof, such as xanthan gum, agar- agar, alginates or tyloses, cellulose derivatives, e.g. carboxymethylcellulose or hy- droxycarboxymethylcellulose, fatty alcohols, monoglycerides and fatty acids, polyvinyl alcohol and polyvinylpyrrolidone. Preference is given to using nonionic thickeners.
  • Suitable cosmetically and/or dermatologically active ingredients are, for example, coloring active ingredients, skin and hair pigmentation agents, tinting agents, tanning agents, bleaches, keratin-hardening substances, antimicrobial active ingredients, pho- tofilter active ingredients, repellent active ingredients, substances with a hyperemic effect, substances with a keratolytic and keratoplastic effect, antidandruff active ingredient, antiphlogistics, substances with a keratinizing effect, active ingredients with an antioxidative or free-radical-scavenging effect, substances which moisturize the skin or keep the skin moist, re-fatting active ingredients, antierythimatous or antiallergic active ingredients, branched fatty acids such as 18-methyleicosanoic acid, and mixtures thereof.
  • Active ingredients which tan the skin artificially and which are suitable for tanning the skin without natural or artificial irradiation with UV rays are, for example, dihydroxyace- tone, alloxan and walnut shell extract.
  • Suitable keratin-hardening substances are usu- ally active ingredients as are also used in antiperspirants, such as, for example, potassium aluminum sulfate, aluminum hydroxychloride, aluminum lactate, etc.
  • Antimicrobial active ingredients are used to destroy microorganisms or to inhibit their growth and thus serve both as preservatives and also as deodorizing substance which reduces the formation or the intensity of body odor.
  • These include, for example, customary preservatives known to the person skilled in the art, such as p-hydroxybenzoic esters, imidazolidinylurea, formaldehyde, sorbic acid, benzoic acid, salicylic acid, etc.
  • deodorizing substances are, for example, zinc ricinoleate, triclosan, undecylenic alkylolamides, triethyl citrate, chlorhexidine etc.
  • Suitable preservatives to be used advantageously according to the invention are listed below with their E number.
  • preservatives or preservative auxiliaries customary in cosmetics dibromodicyanobutane (2-bromo-2- bromomethylglutarodinitrile), 3-iodo-2-propynyl butylcarbamate, 2-bromo-2- nitropropane-1 ,3-diol, imidazolidinylurea, 5-chloro-2-methyl-4-isothiazolin-3-one, 2- chloroacetamide, benzalkonium chloride and benzyl alcohol. + formaldehyde donors.
  • phenyl hydroxyalkyl ethers in particular the com- pound known under the name phenoxyethanol on account of its bactericidal and fungicidal effects on a number of microorganisms.
  • antimicrobial agents are likewise suitable for being incorporated into the preparations according to the invention.
  • Advantageous substances are, for example, 2,4,4'- trichloro-2'-hydroxydiphenyl ether (irgasan), 1 ,6-di(4-chlorophenylbiguanido)hexane (chlorhexidine), 3,4,4'-trichlorocarbanilide, quaternary ammonium compounds, oil of cloves, mint oil, thyme oil, triethyl citrate, farnesol (3,7,1 1 -trimethyl-2, 6,10-dodecatrien- 1 -ol), and the active ingredients or active ingredientcombinations described in the patent laid-open specifications DE-37 40 186, DE 39 38 140, DE-42 04 321 , DE-42 29 707, DE-43 09 372, DE-44 1 1 664, DE-195 41 967, DE-195 43 695, DE-195 43 696, DE-195 47 160, DE-
  • Suitable photofilter active ingredients are substances which absorb UV rays in the UV- B- and/or UV-A region.
  • Suitable UV filters are, for example, 2,4,6-triaryl-1 ,3,5-triazines in which the aryl groups may in each case carry at least one substituent which is pref- erably chosen from hydroxy, alkoxy, specifically methoxy, alkoxycarbonyl, specifically methoxycarbonyl and ethoxycarbonyl and mixtures thereof.
  • substituent which is pref- erably chosen from hydroxy, alkoxy, specifically methoxy, alkoxycarbonyl, specifically methoxycarbonyl and ethoxycarbonyl and mixtures thereof.
  • p- aminobenzoic esters cinnamic esters, benzophenones, camphor derivatives, and pigments which stop UV rays, such as titanium dioxide, talc and zinc oxide.
  • Suitable UV filter substances are any UV-A and UV-B filter substances. The following examples may be mentioned:
  • the cosmetic and dermatological preparations according to the invention may advantageously additionally comprise inorganic pigments which stop UV rays based on metal oxides and/or other metal compounds which are insoluble or slightly soluble in water and chosen from the group of oxides of zinc (ZnO), titanium (Ti02), iron (e.g. Fe203), zirconium (Zr02), silicon (Si02), manganese (e.g. MnO), aluminum (AI203), cerium (e.g. Ce203), mixed oxides of the corresponding metals and mixtures of such oxides.
  • inorganic pigments which stop UV rays based on metal oxides and/or other metal compounds which are insoluble or slightly soluble in water and chosen from the group of oxides of zinc (ZnO), titanium (Ti02), iron (e.g. Fe203), zirconium (Zr02), silicon (Si02), manganese (e.g. MnO), aluminum (AI203), cerium (e.g. Ce203), mixed oxides of the corresponding metals
  • the inorganic pigments can be present here in coated form, i.e. are surface-treated.
  • This surface treatment can consist, for example, in providing the pigments with a thin hydrophobic layer by a method known per se, as described in DE-A-33 14 742.
  • Suitable repellent active ingredients are compounds which are able to repel or drive away certain animals, in particular insects, from humans. These include, for example, 2-ethyl-1 ,3-hexanediol, N,N-diethyl-m-toluamide etc.
  • Suitable hyperemic substances which stimulate the flow of blood through the skin, are e.g. essential oils, such as dwarf pine extract, lavender extract, rosemary extract, juniperberry extract, horse chestnut extract, birch leaf extract, hayflower extract, ethyl acetate, camphor, menthol, peppermint oil, rosemary extract, eucalyptus oil, etc.
  • Suitable keratolytic and keratoplastic substances are, for example, salicylic acid, calcium thioglycolate, thioglycolic acid and its salts, sulfur, etc.
  • Suitable antidandruff active ingredients are, for example, sulfur, sulfur polyethylene glycol sorbitan monooleate, sulfur ricinol polyethoxylate, zinc py- rithione, aluminum pyrithione, etc.
  • Suitable antiinflammatory agents, which counteract skin irritations are, for example, allantoin, bisabolol, dragosantol, camomile extract, panthenol, etc.
  • compositions according to the invention can comprise, as cosmetic and/or pharmaceutical active ingredient (and also if appropriate as auxiliary), at least one cosmetically or pharmaceutically acceptable polymer which differs from the poly- mers which form the polyelectrolyte complex used according to the invention.
  • cosmetically or pharmaceutically acceptable polymer which differs from the poly- mers which form the polyelectrolyte complex used according to the invention.
  • These include, quite generally, cationic, amphoteric and neutral polymers.
  • Suitable polymers are, for example, cationic polymers with the INCI name Poly- qua- ternium, e.g. copolymers of vinylpyrrolidone/N-vinylimidazolium salts (Luviquat FC, Luviquat HM, Luviquat MS, Luviquat&commat, Care), copolymers of
  • Suitable cationic (quaternized) polymers are also Merquat (polymer based on di- methyldiallylammonium chloride), Gafquat (quaternary polymers which are produced by the reaction of polyvinylpyrrolidone with quaternary ammonium compounds), Polymer JR (hydroxyethylcellulose with cationic groups) and plant-based cationic polymers, e.g. guar polymers such as the Jaguar grades from Rhodia.
  • polystyrene resins are also neutral polymers, such as polyvinylpyrrolidones, copolymers of N-vinylpyrrolidone and vinyl acetate and/or vinyl propionate, polysilox- anes, polyvinylcaprolactam and other copolymers with N-vinylpyrrolidone, polyethyle- neimines and salts thereof, polyvinylamines and salts thereof, cellulose derivatives, polyaspartic acid salts and derivatives.
  • neutral polymers such as polyvinylpyrrolidones, copolymers of N-vinylpyrrolidone and vinyl acetate and/or vinyl propionate, polysilox- anes, polyvinylcaprolactam and other copolymers with N-vinylpyrrolidone, polyethyle- neimines and salts thereof, polyvinylamines and salts thereof, cellulose derivatives, polyaspartic acid salt
  • Suitable polymers are also nonionic, water-soluble or water-dispersible polymers or oligomers, such as polyvinylcaprolactam, e.g. Luviskol 0 Plus (BASF), or polyvinylpyr- rolidone and copolymers thereof, in particular with vinyl esters, such as vinyl acetate, e.g. Luviskol 0 VA 37 (BASF), polyamides, e.g. based on itaconic acid and aliphatic diamines, as are described, for example, in DE-A-43 33 238.
  • polyvinylcaprolactam e.g. Luviskol 0 Plus (BASF)
  • BASF Luviskol 0 VA 37
  • polyamides e.g. based on itaconic acid and aliphatic diamines, as are described, for example, in DE-A-43 33 238.
  • Suitable polymers are also amphoteric or zwitterionic polymers, such as the octy- lacrylamide/methyl methacrylate/tert-butylaminoethyl methacrylate/hydroxypropyl methacrylate copolymers obtainable under the names Amphomer (National Starch), and zwitterionic polymers as are disclosed, for example, in the German patent applications DE39 29 973, DE 21 50 557, DE28 17 369 and DE 3708 451. Acrylamidopropyl- trimethylammonium chloride/acrylic acid or methacrylic acid copolymers and alkali metal and ammonium salts thereof are preferred zwitterionic polymers.
  • zwitterionic polymers are methacroylethylbetaine/ methacrylate copolymers, which are available commercially under the name Amersette (AMERCHOL), and copolymers of hydroxyethyl methacrylate, methyl methacrylate, ⁇ , ⁇ -dimethylaminoethyl methacrylate and acrylic acid (Jordapon (D)).
  • Suitable polymers are also nonionic, siloxane-containing, water-soluble or water- dispersible polymers, e.g. polyether siloxanes, such as Tegopren 0 (Goldschmidt) or Besi&commat (Wacker).
  • the formulation base of pharmaceutical compositions according to the invention preferably comprises pharmaceutically acceptable auxiliaries.
  • Pharmaceutically acceptable auxiliaries are those which are known for use in the field of pharmacy, food technology and related fields, in particular those listed in the relevant pharmacopeia (e.g. DAB Ph. Eur. BP NF) and other auxiliaries whose properties do not preclude a physiological application.
  • Suitable auxiliaries may be: lubricants, wetting agents, emulsifying and suspending agents, preserving agents, antioxidants, antiirritatives, chelating agents,
  • emulsion stabilizers emulsion stabilizers, film formers, gel formers, odor-masking agents, resins, hydrocol- loids, solvents, solubility promoters, neutralizing agents, permeation accelerators, pigments, quaternary ammonium compounds, refatting and superfatting agents, ointment, cream or oil base substances, silicone derivatives, stabilizers, sterilizers, propellants, drying agents, opacifiers, thickeners, waxes, softeners, white oil.
  • Formulation in this regard is based on specialist knowledge, as given, for example, in Fiedler, H.P.
  • the active ingredients can be mixed or diluted with a suitable auxiliary (excipient).
  • Excipients may be solid, semisolid or liquid materials which can serve as a vehicle, carrier or medium for the active ingredient.
  • auxiliaries are added, if desired, in the manner known to the person skilled in the art.
  • the polymers and dispersions are suitable as auxiliaries in pharmacy, preferably as or in coating(s) or binder(s) for solid drug forms. They can also be used in creams and as tablet coatings and tablet binders.
  • the skincare compositions according to the invention are, in particular, W/O or O/W skin creams, day and night creams, eye creams, face creams, antiwrinkle creams, an- tisun creams, moisturizing creams, bleach creams, self-tanning creams, vitamin creams, skin lotions, care lotions and moisturizing lotions.
  • Skin cosmetic and dermatological compositions based on the above-described poly- electrolyte complexes exhibit advantageous effects.
  • the polymers can, inter alia, contribute to the moisturization and conditioning of the skin and to an improvement in the feel of the skin.
  • the polymers can also act as thickeners in the formulations.
  • compositions according to the invention can be applied in a form suitable for skincare, such as, for example, as a cream, foam, gel, stick, mousse, milk, spray (pump spray or propellant-containing spray) or lotion.
  • a form suitable for skincare such as, for example, as a cream, foam, gel, stick, mousse, milk, spray (pump spray or propellant-containing spray) or lotion.
  • the skin cosmetic preparations can also comprise further active ingredients and auxiliaries customary in skin cosmetics, as described above. These include preferably emulsifiers, preservatives, perfume oils, cosmetic active ingredients, such as phytantriol, vitamin A, E and C, retinol, bisabolol, pan- thenol, photoprotective agents, bleaches, colorants, tints, tanning agents, collagen, protein hydrolysates, stabilizers, pH regulators, dyes, salts, thickeners, gel formers, consistency regulators, silicones, moisturizers, re-fatting agents and further customary additives.
  • emulsifiers emulsifiers, preservatives, perfume oils, cosmetic active ingredients, such as phytantriol, vitamin A, E and C, retinol, bisabolol, pan- thenol, photoprotective agents, bleaches, colorants, tints, tanning agents, collagen, protein hydrolysates, stabilizers, pH regulators, dyes, salts,
  • Preferred oil and fat components of the skin cosmetic and dermatological compositions are the abovementioned mineral and synthetic oils, such as, for example, paraffins, silicone oils and aliphatic hydrocarbons having more than 8 carbon atoms, animal and vegetable oils, such as, for example, sunflower oil, coconut oil, avocado oil, olive oil, lanolin, or waxes, fatty acids, fatty acid esters, such as, for example, triglycerides of the C6-C30-fatty acids, wax esters, such as, for example, jojoba oil, fatty alcohols, vaseline, hydrogenated lanolin and acetylated lanolin, and mixtures thereof.
  • mineral and synthetic oils such as, for example, paraffins, silicone oils and aliphatic hydrocarbons having more than 8 carbon atoms
  • animal and vegetable oils such as, for example, sunflower oil, coconut oil, avocado oil, olive oil, lanolin, or waxes
  • fatty acids such as, for example, triglycerides of the C6-
  • the beta-glucan according to the invention can also be mixed with conventional polymers if specific properties are to be established.
  • the skin cosmetic and dermatological preparations can additionally also comprise conditioning substances based on silicone compounds.
  • Suitable silicone compounds are, for example, polyalkylsiloxanes, polyarylsiloxanes, polyarylalkylsiloxanes, polyethersiloxanes or silicone resins.
  • the cosmetic or dermatological preparations are prepared by customary methods known to the person skilled in the art.
  • the cosmetic and dermatological compositions are in the form of emulsions, in particular water-in-oil (W/O) or oil-in-water (O/W) emulsions.
  • W/O water-in-oil
  • O/W oil-in-water
  • formulations for example gels, oils, oleogels, multiple emulsions, for example in the form of W/O/W or 0/W/O emulsions, anhydrous ointments or ointment bases, etc.
  • Emulsifier-free formulations such as hydrodispersions, hydrogels or a Pickering emulsion are also advantageous embodiments.
  • the emulsions are prepared by known methods.
  • the emulsions generally comprise customary constituents, such as fatty alcohols, fatty acid esters and, in particular, fatty acid triglycerides, fatty acids, lanolin and derivatives thereof, natural or synthetic oils or waxes and emulsifiers in the presence of water.
  • customary constituents such as fatty alcohols, fatty acid esters and, in particular, fatty acid triglycerides, fatty acids, lanolin and derivatives thereof, natural or synthetic oils or waxes and emulsifiers in the presence of water.
  • a suitable emulsion as W/O emulsion generally comprises an aqueous phase which is emulsified by means of a suitable emulsifier system in an oil or fat phase.
  • a polyelectrolyte complex can be used.
  • Preferred fat components which may be present in the fatty phase of the emulsions are: hydrocarbon oils, such as paraffin oil, purcellin oil, perhydrosqualene and solutions of microcrystalline waxes in these oils; animal or vegetable oils, such as sweet almond oil, avocado oil, calophylum oil, lanolin and derivatives thereof, castor oil, sesame oil, olive oil, jojoba oil, karite oil, hoplostethus oil, mineral oils whose distillation start point under atmospheric pressure is about 250°C and whose distillation end point is 410°C, such as, for example, vaseline oil, esters of saturated or unsaturated fatty acids, such as alkyl myristates, e.g.
  • hydrocarbon oils such as paraffin oil, purcellin oil, perhydrosqualene and solutions of microcrystalline waxes in these oils
  • animal or vegetable oils such as sweet almond oil, avocado oil, calophylum oil, lanolin and derivatives thereof, castor oil, sesame oil,
  • the fatty phase can also comprise silicone oils soluble in other oils, such as dimethyl- polysiloxane, methylphenylpolysiloxane and the silicone glycol copolymer, fatty acids and fatty alcohols.
  • an emulsion according to the invention can be in the form of an O/W emulsion.
  • Such an emulsion usually comprises an oil phase, emulsifiers which stabilize the oil phase in the water phase, and an aqueous phase, which is usually present in thickened form.
  • Suitable emulsifiers are preferably O/W emulsifiers, such as polyglycerol esters, sorbitan esters or partially esterified glycerides.
  • auxiliaries and additives for producing hair cosmetic or skin cosmetic preparations are familiar to the skilled worker and can be found in handbooks of cosmetics, for example Schrader, Klan und Phuren der Kosmetika, Huthig Verlag, Heidelberg, 1989, ISBN 3-7785-1491 -1 .
  • this hair cosmetic or skin cosmetic preparation serves to care for or protect the skin or hair and is the form of an emulsion, a dispersion, a suspension, an aqueous surfactant preparation, a milk, a lotion, a cream, a balsam, an ointment, a gel, a granulation, a dusting powder, a stick product such as, for example, a lipstick, a foam an aerosol or a spray.
  • Suitable emulsions are oil-in-water emulsions and water-in-oil emulsions or microemulsions.
  • the hair cosmetic or skin cosmetic preparation is ordinarily used for application to the skin (topically) or hair.
  • Topical preparations mean in this connection preparations which are suitable for applying the active substances to the skin in fine distribution and preferably in a form which can be absorbed through the skin. Examples suitable for this purpose are aqueous and hydroalcoholic solutions, sprays, foams, foam aerosols, ointments, aqueous gels, emulsions of the O/W or W/O type, microemulsions or cosmetic stick products.
  • the composition comprises a carrier.
  • a preferred carrier is water, a gas, a water-based liquid, an oil, a gel, an emulsion or microemulsion, a dispersion or a mixture thereof. Said carriers are well tolerated by skin. Particularly advantageous for topical preparations are aqueous gels, emulsions or microemulsions.
  • Emulsifiers which can be used are nonionic surfactants, zwitterionic surfactants, am- pholytic surfactants or anionic emulsifiers.
  • the emulsifiers may be present in the composition of the invention in amounts of from 0.1 to 10, preferably 1 to 5, % by weight based on the composition.
  • nonionic surfactant for example a surfactant from at least one of the following groups: adducts of 2 to 30 mol of ethylene oxide and/or 0 to 5 mol of propylene oxide with lin- ear fatty alcohols having 8 to 22 C atoms, with fatty acids having 12 to 22 C atoms and with alkylphenols having 8 to 15 C atoms in the alkyl group;
  • adducts of 2 to 15 mol of ethylene oxide with castor oil and/or hardened castor oil are suitable for mixtures of compounds from a plurality of these substance classes; adducts of 2 to 15 mol of ethylene oxide with castor oil and/or hardened castor oil; partial esters based on linear, branched, unsaturated or saturated C6/22 fatty acids, ricinoleic acid and 12-hydroxystearic acid and glycerol, polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, butyl glucoside, lauryl glucoside) and polyglucosides (e.g.
  • cellulose mono-, di- and trialkyl phosphates and mono-, di- and/or tri-PEG-alkyl phosphates and the salts thereof; wool wax alcohols; polysiloxane-polyalkyl polyether copolymers and corresponding derivatives; mixed esters of pentaerythritol, fatty acids, citric acid and fatty alcohol as disclosed in DE 1 165574 and/or mixed esters of fatty acids having 6 to 22 carbon atoms, methyl glucose and polyols, preferably glycerol or polyglycerol, and polyalkylene glycols; betaines.
  • Zwitterionic surfactants can also be used as emulsifiers.
  • the surface-active com- pounds referred to as zwitterionic surfactants are those having at least one quaternary ammonium group and at least one carboxylate or one sulfonate group in the molecule.
  • Particularly suitable zwitterionic surfactants are the so-called betaines such as the N- alkyl-N,N-dimethylammonium glycinates, for example the cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N,N-dimethylammonium glycinates, for example the co- coacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxylmethyl-3- hydroxyethylimidazolines each having 8 to 18 C atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethyl glycinate.
  • betaines such as the N- alkyl-N,N-dimethylammonium glycinates, for example the cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N,N-dimethylammonium
  • a particularly preferred fatty amide derivative is that known under the CTFA name cocamidopropyl betaine.
  • Emulsifiers which are likewise suitable are ampholytic surfactants.
  • Ampholytic surfactants means surface-active compounds which, apart from a C8/18-alkyl or -acyl group, comprise at least one free amino group and at least one -COOH or S03H group in the molecule and are able to form inner salts.
  • ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N- alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N- alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 18 C atoms in the alkyl group.
  • ampholytic surfactants are N-cocoalkylaminopropionate, cocoa- cylaminoethylaminopropionate and C12/18-acylsarcosine.
  • ampholytic emulsifiers also suitable are quarternary emulsifiers, with particular preference for those of the ester quat type, preferably methyl-quaternized di-fatty acid triethanolamine ester salts.
  • Anionic emulsifiers which can also be employed are alkyl ether sulfates, monoglyceride sulfates, fatty acid sulfates, sulfosuccinates and/or ether carboxylic acids.
  • Suitable oily substances are guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10, carbon atoms, esters of linear C6-C22 fatty acids with linear C6-C22 fatty alcohols, esters of branched C6-C13 carboxylic acids with linear C6-C22 fatty alcohols, esters of linear C6-C22 fatty acids with branched alcohols, especially 2- ethylhexanol, esters of linear and/or branched fatty acids with polyhydric alcohols (such as, for example, propylene glycol, dimerdiol or trimertriol) and/or guerbet alcohols, triglycerides based on C6-C10 fatty acids, liquid mono/di , triglyceride mixtures based on C6-C18 fatty acids, esters of C6-C22 fatty alcohols and/or guerbet alcohols with aromatic carboxylic acids, especially benzoic acid, esters of C2-
  • Oily substances which can be employed are silicone compounds, for example dimethylpolysiloxanes, methylphenyl- polysiloxanes, cyclic silicones and amino , fatty acid , alcohol , polyether , epoxy , fluorine , alkyl and/or glycoside-modified silicone compounds which may at room temperature be both in liquid form and in the form of a resin.
  • the oily substances may be present in the compositions of the invention in amounts of from 1 to 90, preferably 5 to 80, and in particular 10 to 50, % by weight based on the composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation non thérapeutique de bêta-(1,3)-bêta-(1,4)-glucane ayant une masse moléculaire moyenne de 5 000 à 150 000 Da, de préférence de 13 000 à 60 000 Da, en particulier de 20 000 à 40 000 Da, pour l'augmentation de la synthèse du collagène.
PCT/EP2010/067460 2009-11-20 2010-11-15 Utilisation de bêta-(1,3)-bêta-(1,4)-glucane ayant une masse moléculaire moyenne de 5 000 à 150 000 da pour augmentation de synthèse du collagène WO2011061144A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09176635 2009-11-20
EP09176635.2 2009-11-20

Publications (2)

Publication Number Publication Date
WO2011061144A2 true WO2011061144A2 (fr) 2011-05-26
WO2011061144A3 WO2011061144A3 (fr) 2013-12-05

Family

ID=44060107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/067460 WO2011061144A2 (fr) 2009-11-20 2010-11-15 Utilisation de bêta-(1,3)-bêta-(1,4)-glucane ayant une masse moléculaire moyenne de 5 000 à 150 000 da pour augmentation de synthèse du collagène

Country Status (1)

Country Link
WO (1) WO2011061144A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient

Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1165574B (de) 1960-08-08 1964-03-19 Dehydag Gmbh Verfahren zur Herstellung von als Emulgiermittel fuer Salbengrundlagen dienenden Mischestern
DE2150557A1 (de) 1970-10-07 1972-06-08 Minnesota Mining & Mfg Haarfestiger und Verfahren zum Befestigen von Haaren mit einem temporaeren Haarfestiger
DE2817369A1 (de) 1977-04-21 1978-10-26 Oreal Neue copolymerisate, verfahren zu deren herstellung und diese enthaltende kosmetische mittel
DE3314742A1 (de) 1983-04-23 1984-10-25 Degussa Ag, 6000 Frankfurt An der oberflaeche modifizierte natuerliche oxidische oder silikatische fuellstoffe, ein verfahren zur herstellung und deren verwendung
DE3708451A1 (de) 1987-03-16 1988-10-06 Henkel Kgaa Zwitterionische polymere und deren verwendung in haarbehandlungsmitteln
DE3740186A1 (de) 1987-06-24 1989-01-05 Beiersdorf Ag Desodorierende und antimikrobielle zusammensetzung zur verwendung in kosmetischen oder topischen zubereitungen
DE3929973A1 (de) 1989-09-08 1991-03-14 Henkel Kgaa Haarpflegemittel
DE3938140A1 (de) 1989-11-16 1991-08-08 Beiersdorf Ag Desodorierende kosmetische mittel
EP0476063A1 (fr) 1989-06-15 1992-03-25 Alpha Beta Technology Systeme et adjuvant d'acheminement de medicament a base de glucan.
DE4204321A1 (de) 1992-02-13 1993-08-19 Beiersdorf Ag Verfahren zur isolierung und reinigung von fettsaeuren und hydroxyfettsaeuren und verwendungen von hydroxyfettsaeuren sowie zubereitungen, die sie enthalten
DE4229737A1 (de) 1992-09-05 1994-03-10 Beiersdorf Ag Desodorierende kosmetische Mittel mit einem Gehalt an Fettsäuren
DE4229707A1 (de) 1992-09-05 1994-03-10 Beiersdorf Ag Germicide Wirkstoffkombinationen
DE4237081A1 (de) 1992-11-03 1994-05-05 Beiersdorf Ag Desodorierende kosmetische Zubereitungen mit einem Gehalt an Di- oder Triglycerinestern
DE4309372A1 (de) 1993-03-23 1994-09-29 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von Wollwachssäuren und Partialglyceriden
DE4324219A1 (de) 1993-07-20 1995-01-26 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Wollwachssäuren
DE4333238A1 (de) 1993-09-30 1995-04-06 Basf Ag Pyrrolidongruppenhaltige Polyester und Polyamide
DE4411664A1 (de) 1994-04-05 1995-10-12 Beiersdorf Ag Neue desodorierende und antimikrobielle Zusammensetzungen zur Verwendung in kosmetischen oder topischen Zubereitungen
DE4423410A1 (de) 1994-07-04 1996-01-11 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Monocarbonsäureestern von Oligoglyceriden
DE4429467A1 (de) 1994-08-19 1996-02-22 Beiersdorf Ag Desodorierende kosmetische Mittel
WO1996014873A2 (fr) 1994-11-16 1996-05-23 Sri International CONJUGUES DE β-GLUCANES LIES PAR COVALENCE UTILISES POUR UNE ADMINISTRATION CIBLEE
DE19516705A1 (de) 1995-05-06 1996-11-07 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Substanzen
DE19541967A1 (de) 1995-11-10 1997-05-15 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Zusammensetzungen auf der Basis von Partialglyceriden und Arylverbindungen
DE19543695A1 (de) 1995-11-23 1997-05-28 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Zusammensetzungen auf der Basis von alpha-Hydroxyalkansäuren und Squalen
DE19543696A1 (de) 1995-11-23 1997-05-28 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Wirkstoffkombinationen auf der Basis von Partialglyceriden und dialkylsubstituierte Essigsäuren
DE19547160A1 (de) 1995-12-16 1997-06-19 Beiersdorf Ag Verwendung von Zuckerderivaten als antimikrobiell, antimykotisch und/oder antivirale Wirkstoffe
DE19602110A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Zusammensetzungen auf der Basis von Squalen und Sphingolipiden
DE19602108A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
DE19602111A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Mycota, Parasiten, Protozoen und Viren wirksame Zusammensetzungen auf der Basis von Squalen, Sphingolipiden und Fettsäuren
US5676967A (en) 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
DE19631003A1 (de) 1996-08-01 1998-02-05 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Wirkstoffkombinationen auf der Basis von Partialglyceriden und dialkylsubstituierten Essigsäuren
DE19631004A1 (de) 1996-08-01 1998-02-05 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von Wollwsaschsäuren, Partialglyceriden und Arylverbindungen
DE19634019A1 (de) 1996-08-23 1998-02-26 Beiersdorf Ag Gegen Mikroogranismen, Viren, Parasiten und Protozoen wirksame Glycoglycerolipide
WO1998013056A1 (fr) 1996-09-25 1998-04-02 Gracelinc Limited Beta-glucanes et procedes d'extraction a partir de cereales
EP1046394A2 (fr) 1999-04-19 2000-10-25 ImaRx Pharmaceutical Corp. Nouvelles compositions utilisables pour la délivrance de composés dans une cellule
WO2001057092A1 (fr) 2000-02-07 2001-08-09 Granate Seed Limited Procede d'extraction de beta-glucane des cereales et produits obtenus au moyen de ce procede
WO2001087255A1 (fr) 2000-05-16 2001-11-22 Pacific Corporation Composition d'application externe ameliorant la permeabilite de la peau aux ingredients actifs de la composition
WO2002002645A1 (fr) 2000-07-03 2002-01-10 Granate Seed Limited PRODUIT DERIVE DE β-GLUCANE SOLUBLE DANS L'EAU FROIDE ET SON PROCEDE DE FABRICATION
WO2003054077A1 (fr) 2001-12-11 2003-07-03 Ceapro Inc. Compositions de beta-glucane de cereales et procedes de preparation et d'utilisation desdites compositions
WO2005048735A1 (fr) 2003-11-24 2005-06-02 Biovelop International B.V. Fibres alimentaires solubles provenant de grains d'avoine et d'orge, procede de production d'un fragment riche en $g(b)-glucane et utilisation du fragment dans des produits alimentaires, dans des produits pharmaceutiques et dans des produits cosmetiques
WO2005122785A1 (fr) 2004-06-17 2005-12-29 Biovelop International B.V. Concentration de beta-glucanes
WO2006015627A1 (fr) 2004-08-13 2006-02-16 Symrise Gmbh & Co. Kg β-(1,3)-β-(1,4)-GLUCAN EN TANT QUE VEHICULE POUR DES SUBSTANCES CHIMIQUES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3657100A (en) * 1999-03-12 2000-10-04 Biotec Asa Use of water-soluble beta-(1,3) glucans as agents for producing therapeutic skintreatment agents
JP2003192561A (ja) * 2001-12-25 2003-07-09 Asahi Denka Kogyo Kk 皮膚化粧料
DE102009001710A1 (de) * 2009-03-20 2010-09-23 Rovi Cosmetics International Gmbh Kosmetische Zusammensetzung mit Wirkstoffen zur Reduktion von Hautfalten und/oder Reduktion der Tiefe von Hautporen

Patent Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1165574B (de) 1960-08-08 1964-03-19 Dehydag Gmbh Verfahren zur Herstellung von als Emulgiermittel fuer Salbengrundlagen dienenden Mischestern
DE2150557A1 (de) 1970-10-07 1972-06-08 Minnesota Mining & Mfg Haarfestiger und Verfahren zum Befestigen von Haaren mit einem temporaeren Haarfestiger
DE2817369A1 (de) 1977-04-21 1978-10-26 Oreal Neue copolymerisate, verfahren zu deren herstellung und diese enthaltende kosmetische mittel
DE3314742A1 (de) 1983-04-23 1984-10-25 Degussa Ag, 6000 Frankfurt An der oberflaeche modifizierte natuerliche oxidische oder silikatische fuellstoffe, ein verfahren zur herstellung und deren verwendung
DE3708451A1 (de) 1987-03-16 1988-10-06 Henkel Kgaa Zwitterionische polymere und deren verwendung in haarbehandlungsmitteln
DE3740186A1 (de) 1987-06-24 1989-01-05 Beiersdorf Ag Desodorierende und antimikrobielle zusammensetzung zur verwendung in kosmetischen oder topischen zubereitungen
EP0476063A1 (fr) 1989-06-15 1992-03-25 Alpha Beta Technology Systeme et adjuvant d'acheminement de medicament a base de glucan.
DE3929973A1 (de) 1989-09-08 1991-03-14 Henkel Kgaa Haarpflegemittel
DE3938140A1 (de) 1989-11-16 1991-08-08 Beiersdorf Ag Desodorierende kosmetische mittel
DE4204321A1 (de) 1992-02-13 1993-08-19 Beiersdorf Ag Verfahren zur isolierung und reinigung von fettsaeuren und hydroxyfettsaeuren und verwendungen von hydroxyfettsaeuren sowie zubereitungen, die sie enthalten
DE4229737A1 (de) 1992-09-05 1994-03-10 Beiersdorf Ag Desodorierende kosmetische Mittel mit einem Gehalt an Fettsäuren
DE4229707A1 (de) 1992-09-05 1994-03-10 Beiersdorf Ag Germicide Wirkstoffkombinationen
DE4237081A1 (de) 1992-11-03 1994-05-05 Beiersdorf Ag Desodorierende kosmetische Zubereitungen mit einem Gehalt an Di- oder Triglycerinestern
DE4309372A1 (de) 1993-03-23 1994-09-29 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von Wollwachssäuren und Partialglyceriden
DE4324219A1 (de) 1993-07-20 1995-01-26 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Wollwachssäuren
DE4333238A1 (de) 1993-09-30 1995-04-06 Basf Ag Pyrrolidongruppenhaltige Polyester und Polyamide
DE4411664A1 (de) 1994-04-05 1995-10-12 Beiersdorf Ag Neue desodorierende und antimikrobielle Zusammensetzungen zur Verwendung in kosmetischen oder topischen Zubereitungen
DE4423410A1 (de) 1994-07-04 1996-01-11 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Monocarbonsäureestern von Oligoglyceriden
DE4429467A1 (de) 1994-08-19 1996-02-22 Beiersdorf Ag Desodorierende kosmetische Mittel
WO1996014873A2 (fr) 1994-11-16 1996-05-23 Sri International CONJUGUES DE β-GLUCANES LIES PAR COVALENCE UTILISES POUR UNE ADMINISTRATION CIBLEE
US5676967A (en) 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
DE19516705A1 (de) 1995-05-06 1996-11-07 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Substanzen
DE19541967A1 (de) 1995-11-10 1997-05-15 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Zusammensetzungen auf der Basis von Partialglyceriden und Arylverbindungen
DE19543695A1 (de) 1995-11-23 1997-05-28 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Zusammensetzungen auf der Basis von alpha-Hydroxyalkansäuren und Squalen
DE19543696A1 (de) 1995-11-23 1997-05-28 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Wirkstoffkombinationen auf der Basis von Partialglyceriden und dialkylsubstituierte Essigsäuren
DE19547160A1 (de) 1995-12-16 1997-06-19 Beiersdorf Ag Verwendung von Zuckerderivaten als antimikrobiell, antimykotisch und/oder antivirale Wirkstoffe
DE19602110A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Zusammensetzungen auf der Basis von Squalen und Sphingolipiden
DE19602108A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
DE19602111A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Mycota, Parasiten, Protozoen und Viren wirksame Zusammensetzungen auf der Basis von Squalen, Sphingolipiden und Fettsäuren
DE19631004A1 (de) 1996-08-01 1998-02-05 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von Wollwsaschsäuren, Partialglyceriden und Arylverbindungen
DE19631003A1 (de) 1996-08-01 1998-02-05 Beiersdorf Ag Gegen Bakterien, Mycota und Viren wirksame Wirkstoffkombinationen auf der Basis von Partialglyceriden und dialkylsubstituierten Essigsäuren
DE19634019A1 (de) 1996-08-23 1998-02-26 Beiersdorf Ag Gegen Mikroogranismen, Viren, Parasiten und Protozoen wirksame Glycoglycerolipide
WO1998013056A1 (fr) 1996-09-25 1998-04-02 Gracelinc Limited Beta-glucanes et procedes d'extraction a partir de cereales
EP1046394A2 (fr) 1999-04-19 2000-10-25 ImaRx Pharmaceutical Corp. Nouvelles compositions utilisables pour la délivrance de composés dans une cellule
WO2001057092A1 (fr) 2000-02-07 2001-08-09 Granate Seed Limited Procede d'extraction de beta-glucane des cereales et produits obtenus au moyen de ce procede
WO2001087255A1 (fr) 2000-05-16 2001-11-22 Pacific Corporation Composition d'application externe ameliorant la permeabilite de la peau aux ingredients actifs de la composition
WO2002002645A1 (fr) 2000-07-03 2002-01-10 Granate Seed Limited PRODUIT DERIVE DE β-GLUCANE SOLUBLE DANS L'EAU FROIDE ET SON PROCEDE DE FABRICATION
WO2003054077A1 (fr) 2001-12-11 2003-07-03 Ceapro Inc. Compositions de beta-glucane de cereales et procedes de preparation et d'utilisation desdites compositions
WO2005048735A1 (fr) 2003-11-24 2005-06-02 Biovelop International B.V. Fibres alimentaires solubles provenant de grains d'avoine et d'orge, procede de production d'un fragment riche en $g(b)-glucane et utilisation du fragment dans des produits alimentaires, dans des produits pharmaceutiques et dans des produits cosmetiques
WO2005122785A1 (fr) 2004-06-17 2005-12-29 Biovelop International B.V. Concentration de beta-glucanes
WO2006015627A1 (fr) 2004-08-13 2006-02-16 Symrise Gmbh & Co. Kg β-(1,3)-β-(1,4)-GLUCAN EN TANT QUE VEHICULE POUR DES SUBSTANCES CHIMIQUES

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Fundamentals and formulations of cosmetics", 1989, HUTHIG VERLAG, article "handbooks of cosmetics, for example Schrader, Grundlagen und Rezepturen der Kosmetika"
FIEDLER, H.P.: "Cosmetics and related fields", 1996, ECV-EDITIO-KANTOR-VERLAG, article "Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete [Lexicon of Auxiliaries for Pharmacy"
HECKER, K. D.; M. L. MEIER ET AL.: "Barley Beta-Glucan Is Effective As a Hypocholesterolaemic Ingredient in Foods", JOURNAL OF THE SCIENCE OF FOOD & AGRICULTURE, vol. 77, no. 2, 1998, pages 179 - 183, XP000752090, DOI: doi:10.1002/(SICI)1097-0010(199806)77:2<179::AID-JSFA23>3.0.CO;2-0
JONES, A.: "Barley beta-glucan", CEREAL FOODS WORLD, vol. 38, 1993, pages 160 - 161
KEOGH GF; COOPER GJ; MULVEY TB ET AL.: "Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men", AM J CLIN NUTR., vol. 78, 2003, pages 711 - 718
NEWMAN, R.; C. W. NEWMAN: "The hypocholesterolemic function of barley beta-glucans", CEREAL FOODS WORLD, vol. 34, 1989, pages 883 - 886, XP009059177
SCHRADER, GRUNDLAGEN: "Rezepturen der Kosmetika", 1989, HUTHIG VERLAG
SCHRADER, GRUNDLAGEN; REZEPTUREN DER KOSMETIKA: "Fundamentals and Formulations of Cosmetics", 1989, HUTHIG BUCH VERLAG
WOOD, PJ: "Oat Bran Ed PJ Wood", vol. 1, 1993, AMERICAN ASSOCIATION OF CEREAL CHEMISTS, INC., pages: 5

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11633451B2 (en) 2016-03-31 2023-04-25 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US11998575B2 (en) 2016-03-31 2024-06-04 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient

Also Published As

Publication number Publication date
WO2011061144A3 (fr) 2013-12-05

Similar Documents

Publication Publication Date Title
RU2499607C2 (ru) Косметические препараты на основе молекулярно впечатанных полимеров
US20080220031A1 (en) Dermocosmetic Preparations
US10159632B2 (en) Cosmetic compositions comprising hyaluronan biosynthesis promoting agents
US20100247689A1 (en) Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue
WO2008055931A1 (fr) Utilisation de résilines naturelles, recombinantes et synthétiques en cosmétique
CA2708554A1 (fr) Compositions antipelliculaires contenant des peptides
JP2005535566A (ja) 抗酸化製剤
DE19540749A1 (de) Kosmetische Zubereitungen mit einem wirksamen Gehalt an Glycosylglyceriden
JP7446362B2 (ja) セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物、製造、および使用
BR102013001531A2 (pt) composições
JP2005526782A (ja) 化粧用製剤用の油相
EP3645125A1 (fr) Méthode de solubilisation de produits cosmétiques peu solubles dans l&#39;eau
KR102015173B1 (ko) 저자극성 피부 미백용 화장료 조성물
WO2011061144A2 (fr) Utilisation de bêta-(1,3)-bêta-(1,4)-glucane ayant une masse moléculaire moyenne de 5 000 à 150 000 da pour augmentation de synthèse du collagène
JP2002539144A (ja) 化粧品調合物
US9241891B2 (en) Personal care compositions comprising self-assembling peptides
US20230248626A1 (en) Compositions Comprising (Bio)-Alkanediols
KR20050105501A (ko) 에페루아 팔카타의 추출물 및/또는 그의 성분을 함유하는제제
JP2020531552A (ja) 生理学的冷涼活性成分の使用、及びそのような活性成分を含む組成物
KR102006951B1 (ko) 비듬 또는 가려움 예방 및 개선용 화장료 조성물
JP2005509513A (ja) 乳化剤混合物
JP2005179286A (ja) ヒアルロン合成促進剤の皮膚老化防止剤への利用
DE102006051088A1 (de) Verwendung der 3,3&#39;-Dihydroxyisorenieratin und verwandter Carotinoide
CN113194910B (zh) 皮肤再生用化妆料组合物
JP2002212026A (ja) 美肌用皮膚外用剤

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 10781649

Country of ref document: EP

Kind code of ref document: A2